Skip to content

Calliditas Therapeutics AB

CIK 0001795579

Revenue (TTM)
Q2 Jun 2024
Net Income (TTM)
−538.89M
−13.1% YoY Q2 Jun 2024
EPS Diluted (TTM)
−10.16
−11.7% YoY Q2 Jun 2024
Gross Margin
Q2 Jun 2024
Operating Margin
Q2 Jun 2024
Net Margin
Q2 Jun 2024
Free Cash Flow (TTM)
Q2 Jun 2024
Cash
797.28M
Q2 Jun 2024
Total Debt
Q2 Jun 2024
Shares Outstanding
59.58M sh
Q2 Jun 2024

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings